Navigation Links
New Study Shares Insights for Competitive Intelligence Policies, Ethics and Data Collection
Date:1/30/2009

CHAPEL HILL, N.C., Jan. 30 /PRNewswire/ -- New research has shown that companies can take advantage of opportunities and manage risk by collecting and understanding intelligence through the competitive or business intelligence function. In an effort to better understand the best practices in developing effective and legally sound data collection procedures, a recent study was conducted by Best Practices, LLC, with insights available in the newly published report, "Competitive Intelligence Policies, Ethics, and Data Collection: Navigating the Gray Zone." This benchmarking study was conducted to understand how U.S. pharmaceutical and biotechnology organizations can optimize their CI/BI operations while working within defined guidelines.

The research examined a number of topics, including:

  • Identifying CI information sources and what is being collected
  • Understanding how CI groups work with legal groups to develop standard operating procedures for data collection that are in the best interests of the organization as a whole
  • Maximizing the CI department's ability to deliver results

The performance metrics found in this study were gathered from industry experts including those from such top companies as Amgen, Baxter, Eli Lilly, Merck, Roche and Wyeth.

Key findings from the study include:

  • Multiple data sources are vital to effective CI - utilize triangulation to develop the most accurate projections
  • Develop the right skill sets, processes and use appropriate third party vendors to collect and review data over time to distill relevant, actionable information
  • Ensure the function and its resources evolve over time to ensure alignment with internal customers and to continue to provide the most current, accurate intelligence
  • Talk with employees across functions inside your company to identify intelligence gaps
  • Hold Vendors to Strict Standards
  • CI Guidelines Enable Success
  • Work collaboratively with Legal to protect the company and obtain buy-in and support
  • Involve upper management to ensure visibility of the value provided to the company by the CI function
  • CI must help educate the employees who make inappropriate or unattainable requests for information
  • Link CI to the financial perspective to gain clout in the company

For more information on this report, contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr976.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):